In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.

Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 9601804 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7039 (Electronic) Linking ISSN: 10833021 NLM ISO Abbreviation: J Mammary Gland Biol Neoplasia Subsets: MEDLINE

Publication: 1999- : New York, NY : Kluwer Academic/Plenum Publishers
Original Publication: New York : Plenum Press, c1996-

Breast Neoplasms*/drug therapy; Animals ; Cell Line ; Disease Models, Animal ; Female ; Heterografts ; Humans ; Mice ; Rats ; Swine ; Xenograft Model Antitumor Assays ; Zebrafish

Historically, human breast cancer has been modeled largely in vitro using long-established cell lines primarily in two-dimensional culture, but also in three-dimensional cultures of varying cellular and molecular complexities. A subset of cell line models has also been used in vivo as cell line-derived xenografts (CDX). While outstanding for conducting detailed molecular analysis of regulatory mechanisms that may function in vivo, results of drug response studies using long-established cell lines have largely failed to translate clinically. In an attempt to address this shortcoming, many laboratories have succeeded in developing clinically annotated patient-derived xenograft (PDX) models of human cancers, including breast, in a variety of host systems. While immunocompromised mice are the predominant host, the immunocompromised rat and pig, zebrafish, as well as the chicken egg chorioallantoic membrane (CAM) have also emerged as potential host platforms to help address perceived shortcomings of immunocompromised mice. With any modeling platform, the two main issues to be resolved are criteria for "credentialing" the models as valid models to represent human cancer, and utility with respect to the ability to generate clinically relevant translational research data. Such data are beginning to emerge, particularly with the activities of PDX consortia such as the NCI PDXNet Program, EuroPDX, and the International Breast Cancer Consortium, as well as a host of pharmaceutical companies and contract research organizations (CRO). This review focuses primarily on these important aspects of PDX-related research, with a focus on breast cancer.
(© 2022. The Author(s).)

Erratum in: J Mammary Gland Biol Neoplasia. 2022 Jul 26;:. (PMID: 35881233)

Mol Oncol. 2007 Jun;1(1):84-96. (PMID: 18516279)
Front Oncol. 2018 Nov 30;8:559. (PMID: 30560086)
BMC Genomics. 2016 Aug 22;17 Suppl 7:525. (PMID: 27556158)
Nat Med. 2011 Oct 23;17(11):1514-20. (PMID: 22019887)
Microbiol Sci. 1985 Dec;2(12):367-8. (PMID: 3939992)
Cancer Res. 2013 Aug 1;73(15):4885-97. (PMID: 23737486)
J Immunol. 2001 Sep 15;167(6):3033-42. (PMID: 11544286)
Clin Cancer Res. 2013 Mar 15;19(6):1512-24. (PMID: 23340294)
J Biomed Inform. 2015 Oct;57:456-64. (PMID: 26325296)
Mol Cell Proteomics. 2018 Nov;17(11):2270-2283. (PMID: 30093420)
Dev Comp Immunol. 2004 Jan;28(1):9-28. (PMID: 12962979)
J Hematol Oncol. 2016 Sep 21;9(1):92. (PMID: 27655386)
Nature. 2012 Mar 28;483(7391):603-7. (PMID: 22460905)
Cell. 2016 Sep 22;167(1):260-274.e22. (PMID: 27641504)
Transplantation. 2020 Apr;104(4):715-723. (PMID: 31764762)
J Exp Med. 1913 Apr 1;17(4):482-93. (PMID: 19867659)
Nat Genet. 2021 Jan;53(1):86-99. (PMID: 33414553)
PLoS One. 2013 Apr 16;8(4):e61801. (PMID: 23613942)
Vet Immunol Immunopathol. 2016 Jul;175:1-6. (PMID: 27269786)
Clin Cancer Res. 2015 Mar 1;21(5):969-75. (PMID: 25573382)
Front Oncol. 2019 Jan 22;9:9. (PMID: 30723704)
Breast Cancer Res Treat. 2018 Jul;170(2):221-234. (PMID: 29532339)
Stem Cells. 2014 Oct;32(10):2571-82. (PMID: 24891218)
Arch Dermatol Res. 1997 Mar;289(4):213-8. (PMID: 9143737)
FASEB J. 2013 Feb;27(2):703-11. (PMID: 23150522)
Lab Anim. 1997 Apr;31(2):163-8. (PMID: 9175014)
Nature. 1978 Jul 27;274(5669):365-6. (PMID: 307688)
BMC Cancer. 2019 Mar 12;19(1):220. (PMID: 30871481)
Lab Anim. 2018 Aug;52(4):402-412. (PMID: 29325489)
J Infect Dis. 1995 Oct;172(4):974-82. (PMID: 7561218)
Nat Methods. 2007 Jul;4(7):551-3. (PMID: 17572681)
Dis Model Mech. 2016 Jul 1;9(7):749-57. (PMID: 27149990)
Cell. 2008 Dec 26;135(7):1287-98. (PMID: 19109897)
Mol Cell Proteomics. 2004 Jan;3(1):73-81. (PMID: 14593079)
Cell Tissue Res. 1993 Oct;274(1):163-72. (PMID: 7694800)
Blood. 1996 Feb 1;87(3):956-67. (PMID: 8562967)
Cell Rep. 2017 Nov 14;21(7):1953-1967. (PMID: 29141225)
Cancer Discov. 2014 Sep;4(9):998-1013. (PMID: 25185190)
Nat Methods. 2014 Aug;11(8):821-4. (PMID: 25042784)
Clin Exp Immunol. 2008 Nov;154(2):270-84. (PMID: 18785974)
Nat Rev Drug Discov. 2004 Aug;3(8):711-5. (PMID: 15286737)
Cell Cycle. 2011 Nov 1;10(21):3751-7. (PMID: 22033190)
Nat Commun. 2019 May 21;10(1):2244. (PMID: 31113942)
Front Immunol. 2020 Feb 06;11:100. (PMID: 32117254)
IEEE/ACM Trans Comput Biol Bioinform. 2021 Mar-Apr;18(2):575-582. (PMID: 31150344)
Cancer Lett. 2012 Dec 29;326(1):69-78. (PMID: 22841668)
Nat Rev Genet. 2007 May;8(5):353-67. (PMID: 17440532)
Cancer Genet. 2011 Aug;204(8):447-57. (PMID: 21962895)
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13. (PMID: 22068913)
Clin Exp Immunol. 2009 Jul;157(1):104-18. (PMID: 19659776)
NPJ Breast Cancer. 2020 Jul 21;6:30. (PMID: 32715085)
Cell Immunol. 1996 Aug 1;171(2):186-99. (PMID: 8806787)
Curr Pharm Des. 2006;12(11):1421-7. (PMID: 16611125)
Science. 2004 Apr 2;304(5667):104-7. (PMID: 15064419)
Breast Cancer Res Treat. 2012 Sep;135(2):415-32. (PMID: 22821401)
Pharmaceuticals (Basel). 2019 Dec 24;13(1):. (PMID: 31878274)
Clin Cancer Res. 2008 Oct 15;14(20):6456-68. (PMID: 18927285)
Blood. 2005 Sep 1;106(5):1565-73. (PMID: 15920010)
Biomed Res Int. 2015;2015:629754. (PMID: 26539518)
FASEB J. 2019 Jan;33(1):140-150. (PMID: 29944447)
Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098)
J Immunol. 2005 May 15;174(10):6477-89. (PMID: 15879151)
Cell Rep. 2013 Sep 26;4(6):1116-30. (PMID: 24055055)
Sci Rep. 2016 Apr 27;6:25222. (PMID: 27118081)
Neoplasia. 2018 May;20(5):443-455. (PMID: 29574251)
Stem Cell Reports. 2018 Aug 14;11(2):514-521. (PMID: 29983387)
BMC Gastroenterol. 2010 Jul 22;10:83. (PMID: 20649994)
Am J Transl Res. 2010 Nov 01;3(1):114-20. (PMID: 21139811)
Trends Immunol. 2018 Sep;39(9):748-763. (PMID: 30077656)
Blood. 2002 Nov 1;100(9):3175-82. (PMID: 12384415)
Acta Histochem. 1988;83(2):121-4. (PMID: 3138880)
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7260-5. (PMID: 24799706)
Zebrafish. 2017 Feb;14(1):77-79. (PMID: 27841973)
J Immunol. 2010 Sep 1;185(5):2710-20. (PMID: 20668220)
Cancer Res. 2018 Jan 15;78(2):489-500. (PMID: 29183891)
J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):111. (PMID: 27815673)
Nat Med. 2015 Nov;21(11):1318-25. (PMID: 26479923)
Cell. 2019 Jun 13;177(7):1903-1914.e14. (PMID: 31031007)
Nature. 2016 Feb 25;530(7591):391. (PMID: 26911756)
Breast Cancer Res Treat. 2012 Oct;135(3):913-22. (PMID: 22941572)
Clin Cancer Res. 2007 Jul 1;13(13):3989-98. (PMID: 17606733)
Nat Rev Drug Discov. 2019 Jul;18(7):495-496. (PMID: 31267067)
Science. 2002 Jul 5;297(5578):99-102. (PMID: 12098699)
Br J Cancer. 2001 May 18;84(10):1424-31. (PMID: 11355958)
Evol Med Public Health. 2016 May 21;2016(1):170-6. (PMID: 27121451)
Cancer Res. 1952 Dec;12(12):915-7. (PMID: 13009682)
Br J Cancer. 1982 May;45(5):786-9. (PMID: 7082561)
J Natl Cancer Inst. 1981 May;66(5):843-8. (PMID: 6939928)
J Clin Invest. 2018 Apr 2;128(4):1283-1299. (PMID: 29480818)
Precis Clin Med. 2019 Sep;2(3):140-151. (PMID: 31598385)
PLoS One. 2012;7(8):e30207. (PMID: 22879872)
Breast Cancer Res. 2014 Apr 07;16(2):R36. (PMID: 24708766)
Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-14.38.11. (PMID: 26995547)
BMC Cancer. 2009 Apr 28;9:128. (PMID: 19400945)
Mol Ther Nucleic Acids. 2019 Sep 6;17:164-174. (PMID: 31265947)
Cell. 1992 Mar 6;68(5):869-77. (PMID: 1547488)
Breast Cancer Res. 2017 Dec 06;19(1):130. (PMID: 29212525)
ILAR J. 2015;56(1):1-6. (PMID: 25991694)
Cell Stem Cell. 2012 Jun 14;10(6):753-758. (PMID: 22704516)
Vet Pathol. 2001 Sep;38(5):483-90. (PMID: 11572555)
Bioinformatics. 2015 May 15;31(10):1655-62. (PMID: 25573920)
Nat Commun. 2015 Feb 10;6:6246. (PMID: 25665714)
Cell. 2002 Mar 22;108(6):781-94. (PMID: 11955432)
Mol Ther Nucleic Acids. 2020 Sep 4;21:676-686. (PMID: 32759058)
Cells. 2019 May 06;8(5):. (PMID: 31064068)
BMC Cancer. 2003 Apr 24;3:13. (PMID: 12713671)
Breast Cancer Res. 2015 Jan 09;17:3. (PMID: 25572662)
Exp Anim. 2018 May 10;67(2):139-146. (PMID: 29162766)
Breast Cancer Res. 2019 Aug 28;21(1):98. (PMID: 31462307)
Exp Pathol (Jena). 1978;15(5):241-9. (PMID: 365563)
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. (PMID: 22508028)
Dis Model Mech. 2016 Jul 1;9(7):811-20. (PMID: 27482819)
Nat Cancer. 2022 Feb;3(2):232-250. (PMID: 35221336)
BMC Genomics. 2013 May 15;14:332. (PMID: 23676093)
Br J Haematol. 2011 Jun;153(6):786-9. (PMID: 21517816)
Exp Hematol. 2018 Nov;67:18-31. (PMID: 30125602)
Gastroenterology. 2009 Dec;137(6):2136-45.e1-7. (PMID: 19747919)
Cancer Cell. 2022 Jan 10;40(1):26-35. (PMID: 34951956)
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. (PMID: 28821924)
Dev Dyn. 2005 Aug;233(4):1560-70. (PMID: 15968639)
Cell. 2008 Dec 26;135(7):1299-310. (PMID: 19109898)
Nat Biotechnol. 2014 Jan;32(1):40-51. (PMID: 24406927)
J Cell Biochem. 2011 Oct;112(10):2850-64. (PMID: 21618587)
Cancer Res. 2007 Apr 1;67(7):2927-31. (PMID: 17409396)
Neoplasia. 2017 Aug;19(8):628-636. (PMID: 28658648)
Nature. 2015 Feb 19;518(7539):422-6. (PMID: 25470049)
Int Immunol. 2009 Jul;21(7):843-58. (PMID: 19515798)
Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):9-15. (PMID: 19956064)
Cell. 1992 Mar 6;68(5):855-67. (PMID: 1547487)
PLoS One. 2020 Oct 7;15(10):e0240169. (PMID: 33027304)
Breast Cancer Res. 2019 Mar 6;21(1):36. (PMID: 30841919)
Sci Rep. 2019 Apr 11;9(1):5901. (PMID: 30976061)
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760)
Am J Cancer Res. 2018 Aug 01;8(8):1642-1660. (PMID: 30210932)
BMC Cancer. 2017 Aug 2;17(1):513. (PMID: 28768489)
Am J Pathol. 1956 Mar-Apr;32(2):271-85. (PMID: 13302398)
Blood. 2003 Oct 1;102(7):2522-31. (PMID: 12791667)
Adv Appl Microbiol. 1974;17(0):295-309. (PMID: 4609142)
Haematologica. 2019 Dec 19;105(10):2391-2399. (PMID: 33054079)
Nat Med. 2006 Nov;12(11):1316-22. (PMID: 17057712)
BMC Immunol. 2012 Nov 08;13:60. (PMID: 23136839)
Int J Cancer. 2019 Oct 1;145(7):1902-1912. (PMID: 30859564)
Histochem Cell Biol. 2008 Dec;130(6):1119-30. (PMID: 19005674)
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. (PMID: 27573169)
Blood. 2006 Jul 15;108(2):487-92. (PMID: 16410443)
Clin Cancer Res. 2021 Sep 1;27(17):4696-4699. (PMID: 34078650)
Medicina (Kaunas). 2009;45(2):123-31. (PMID: 19289902)
Anticancer Res. 2015 Dec;35(12):6521-8. (PMID: 26637866)
F1000Res. 2020 Oct 9;9:1219. (PMID: 34249349)
J Immunol. 1995 Jan 1;154(1):180-91. (PMID: 7995938)
J Clin Med. 2019 Oct 24;8(11):. (PMID: 31652963)
Cancer Metastasis Rev. 2016 Dec;35(4):547-573. (PMID: 28025748)
Oncotarget. 2016 Aug 9;7(32):50914-50926. (PMID: 27463006)
iScience. 2021 Nov 12;24(12):103423. (PMID: 34849474)
Nat Commun. 2021 Aug 24;12(1):5086. (PMID: 34429404)
Biores Open Access. 2012 Apr;1(2):63-8. (PMID: 23514746)
Cancer Cell. 2006 Dec;10(6):515-27. (PMID: 17157791)
Exp Hematol. 1999 Sep;27(9):1418-27. (PMID: 10480433)
Cancer Res. 2017 Nov 1;77(21):e62-e66. (PMID: 29092942)
Mol Cancer Ther. 2018 Nov;17(11):2481-2489. (PMID: 30206106)
Science. 1990 Jun 22;248(4962):1517-23. (PMID: 2360047)
Nature. 2019 Jan;565(7738):E5-E6. (PMID: 30559381)
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8234-E8243. (PMID: 28835536)
Leukemia. 2017 Jan;31(1):151-158. (PMID: 27363283)
J Neurosurg. 2009 Aug;111(2):238-46. (PMID: 19199503)
Cancer Cell. 2016 Mar 14;29(3):407-422. (PMID: 26947176)
Nat Rev Cancer. 2017 Apr;17(4):254-268. (PMID: 28104906)
Methods Mol Biol. 2019;1953:241-252. (PMID: 30912026)
Vet Pathol. 2012 Mar;49(2):344-56. (PMID: 21441112)
J Pathol. 2012 Aug;227(4):431-45. (PMID: 22374800)
Curr Top Microbiol Immunol. 2008;324:149-65. (PMID: 18481459)
Nature. 2012 Mar 28;483(7391):570-5. (PMID: 22460902)
Cancer. 2014 Jul 1;120(13):2006-15. (PMID: 24705963)
BMC Cancer. 2011 Jun 13;11:241. (PMID: 21668953)
Cancer Discov. 2015 Nov;5(11):1210-23. (PMID: 26482930)
Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. (PMID: 22406983)
Breast Cancer Res. 2009;11(3):R39. (PMID: 19549321)
Nat Med. 2018 May;24(4):505-511. (PMID: 29578538)
EMBO Mol Med. 2017 Feb;9(2):137-153. (PMID: 28028012)
Breast Dis. 2007;28:39-51. (PMID: 18057542)
Int J Cancer. 2011 Nov 1;129(9):2194-206. (PMID: 21544806)
Nature. 1983 Feb 10;301(5900):527-30. (PMID: 6823332)
J Pathol. 2019 Mar;247(3):287-292. (PMID: 30430577)
Nature. 2018 Aug;560(7718):325-330. (PMID: 30089904)
Mech Dev. 2016 Aug;141:70-77. (PMID: 27178379)
Clin Cancer Res. 2012 Oct 1;18(19):5314-28. (PMID: 22825584)
Exp Cell Res. 2014 Nov 1;328(2):314-24. (PMID: 24972385)
PLoS One. 2014 May 16;9(5):e97950. (PMID: 24835641)
Cancer Res. 2009 Apr 15;69(8):3364-73. (PMID: 19351829)
Nature. 1988 Sep 15;335(6187):256-9. (PMID: 2970594)
Genet Res. 1966 Dec;8(3):295-309. (PMID: 5980117)
PLoS One. 2019 Nov 20;14(11):e0225532. (PMID: 31747424)
Int J Mol Med. 1999 Dec;4(6):593-6. (PMID: 10567667)
J Immunol. 2014 Aug 1;193(3):1496-503. (PMID: 24973446)
J Immunol. 2015 Oct 1;195(7):3171-9. (PMID: 26320255)
Sci Rep. 2019 Dec 11;9(1):18911. (PMID: 31827124)
J Exp Med. 2016 Nov 14;213(12):2575-2589. (PMID: 27810924)
Cell Rep. 2012 Sep 27;2(3):685-94. (PMID: 22981234)
PLoS Comput Biol. 2015 Sep 29;11(9):e1004498. (PMID: 26418249)
Genome Biol. 2013;14(10):R110. (PMID: 24176112)
PLoS One. 2015 Jun 24;10(6):e0130935. (PMID: 26107941)
FASEB J. 2018 Mar;32(3):1537-1549. (PMID: 29146734)
Cancer Res. 2020 Jun 1;80(11):2286-2297. (PMID: 32152150)
Cell. 2016 Jul 28;166(3):740-754. (PMID: 27397505)

P30 CA125123 United States CA NCI NIH HHS; R01 CA224867 United States CA NCI NIH HHS; U54 CA224076 United States CA NCI NIH HHS

Keywords: Immunodeficient mouse and rat models; In vivo models; Patient-derived xenograft; Preclinical drug screening; Preclinical trials

Date Created: 20220613 Date Completed: 20220908 Latest Revision: 20240214

20240214

PMC9433358

10.1007/s10911-022-09520-y

35697909